News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Strong interim result in Phase I/IIa DIABECELL® trial

Living Cell Technologies Limited
Company Announcement

Strong interim results in Argentinian Phase I/IIa DIABECELL® trial

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the results of an interim analysis of its Argentinian Phase I/IIa clinical trial for DIABECELL®, a breakthrough treatment for people with unstable type 1 diabetes.

The results clearly demonstrated a clinically significant reduction in HbA1c, insulin dose and unaware hypoglycaemia, with greater benefit being seen in the patient group receiving the higher dose of DIABECELL.

The trial, which is ongoing, involves eight patients split into two groups of four. Group one received two 5,000 IEQ/kg doses of DIABECELL (islet equivalents per kilogram of body weight). Group two received two 10,000 IEQ/kg doses of DIABECELL. In both groups, the second dose was implanted 12 weeks after the first. At the time of this interim analysis, group one patients were at 24 weeks follow up after the second transplant, and group two patients were at 12 weeks follow up after the second transplant.

In the second group of patients (those receiving the higher dose of two implants of 10,000 IEQ/kg) the most significant clinical benefits were:

• average insulin dose reduced by 20%
• a reduction of HbA1c from a pre-transplant average of 8.6% to an average of 6.7% at 12 weeks following the second implant
• up to 70% reduction in unaware hypoglycaemic events.

“Most type 1 diabetic patients who cannot attain reasonable control of their disease by conventional intensive insulin treatment would welcome the degree of control achieved with two doses of DIABECELL,” said Professor Bob Elliott, Chief Scientific and Medical Officer, LCT. “The reduction in both average daily insulin dose and HbA1c is clear demonstration of the positive effect of the DIABECELL transplant.”

DIABECELL is the first islet transplant treatment that does not require ongoing administration of debilitating immunosuppression drugs. DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.

“This interim analysis has been used to inform our 20 patient Phase IIb study, the start of which has also been announced today,” said Dr Andrea Grant, Chief Executive, LCT. “With each trial analysis we grow increasingly confident that DIABECELL will bring many benefits to patients with unstable type 1 diabetes, and we remain intently focused on reaching the market by 2016.”


– Ends –

For further information: www.lctglobal.com

About DIABECELL
Diabetes is usually treated with insulin replacement. A serious and potentially fatal complication associated with intensive insulin replacement therapy is unaware hypoglycaemia. Episodes of unaware hypoglycaemia occur when, without associated symptoms or warning, blood glucose levels drop suddenly. Some patients require significant time and resources from specialist healthcare professionals and have a poor prognosis: lower quality of life, more micro vascular and pregnancy complications and shortened life expectancy.
Treatment with DIABECELL® involves transplanting pig pancreatic islet cells into a patient’s abdomen to boost insulin production and help regulate blood glucose levels. The cells are encapsulated with IMMUPEL™ to prevent the immune system rejecting them as foreign. This proprietary technology ensures the cells can deliver their beneficial effects without the patient requiring immunosuppressant drugs.
DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.
For a summary of DIABECELL’s clinical trial programme please see the DIABECELL clinical trial update on LCT’s website www.lctglobal.com or DIABECELL clinical trial update.

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson’s disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Scoop Review Of Books: Q&A: Prue Hyman On ‘Hopes Dashed?’

For Scoop Review of Books, Alison McCulloch interviewed Prue Hyman about her new book, part of the BWB Texts series, Hopes Dashed? The Economics of Gender Inequality More>>

Gordon Campbell: On Chuck Berry (And James Comey, And Bill English)

Back when many people were still treating rock’n’roll as a passing fad – was calypso going to be the new thing? – Chuck Berry knew that it had changed popular music forever. What is even more astonishing is that this 30-ish black r&b musician from a middle class family in St Louis could manage to recreate the world of white teenagers, at a time when the very notion of a “teenager” had just been invented. More>>

Howard Davis Review:
The Baroque Fusion Of L'arpeggiata

Named after a toccata by German composer Girolamo Kapsberger, L'Arpeggiata produces its unmistakable sonority mainly from the resonance of plucked strings, creating a tightly-woven acoustic texture that is both idiosyncratic and immediately identifiable. Director Christina Pluhar engenders this distinctive tonality associated with the ensemble she founded in 2000 by inviting musicians and vocalists from around the world to collaborate on specific projects illuminated by her musicological research. More>>

African Masks And Sculpture: Attic Discovery On Display At Expressions Whirinaki

Ranging from masks studded with nails and shards of glass to statues laden with magical metal, the works are from ethnic groups in nine countries ranging from Ivory Coast to the Democratic Republic of the Congo. More>>

Obituary: Andrew Little Remembers Murray Ball

“Murray mined a rich vein of New Zealand popular culture and exported it to the world. Wal and Dog and all the other Kiwi characters he crafted through Footrot Flats were hugely popular here and in Australia, Europe and North America." More>>

ALSO:

Organised Choas: NZ Fringe Festival 2017 Awards

Three more weeks of organised chaos have come to an end with the Wellington NZ Fringe Arts Festival Awards Ceremony as a chance to celebrate all our Fringe artists for their talent, ingenuity, and chutzpah! More>>

ALSO:

Wellington.Scoop: Wellington Writer Wins $US165,000 Literature Prize

Victoria University of Wellington staff member and alumna Ashleigh Young has won a prestigious Windham-Campbell Literature Prize worth USD$165,000 for her book of essays Can You Tolerate This? More>>

ALSO:

Scoop Review Of Books: We’re All Lab Rats

A couple of years ago, there were reports that Silicon Valley executives were sending their children to tech-free schools. It was a story that dripped of irony: geeks in the heart of techno-utopia rejecting their ideology when it came to their own kids. But the story didn’t catch on, and an awkward question lingered. Why were the engineers of the future desperate to part their gadgets from their children? More>>

  • CensusAtSchool - Most kids have no screen-time limits
  • Netsafe - Half of NZ high school students unsupervised online
  • Get More From Scoop

     
     

    LATEST HEADLINES

     
     
     
     
    Health
    Search Scoop  
     
     
    Powered by Vodafone
    NZ independent news